Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Opioid Relapse
NCT01605539Phase 2Completed
- Start
- May 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in opioid use disorder (OUD) (3 arms). Primary endpoints: Changes in Cue-Induced In-Clinic Craving and Changes in Out-of-Clinic Craving. Started May 2012; status: completed.
02
Drugs
cannabidiol
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT01605539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01605539.